Taisho Pharmaceutical Co., Ltd.
🇯🇵Japan
Development and Validation of a Driving Simulator for Evaluating the Residual Effects of Drugs on Driving Performance - Sensitivity Analysis Using Zopiclone as a Positive Control
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04108351
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Fukuoka, Japan
🇯🇵The medical facility selected by Taisho Pharmaceutical Co., Ltd, Fukuoka, Japan
Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects
Phase 2
Completed
- Conditions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT04087707
- Locations
- 🇯🇵
Sumida Hospital, Sumida-ku, Tokyo, Japan
An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 401
- Registration Number
- NCT04077567
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03595202
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
Clinical Study of TS-143 in Healthy Adult Male Subjects (Single-Dose Administration)
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03591133
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT03581071
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Multiple Locations, Japan
Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #3
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT03572985
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Fukuoka, Japan
Safety and Efficacy of SFPP in Knee Osteoarthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 313
- Registration Number
- NCT03434197
- Locations
- 🇮🇩
Klinik Perisai Husada, Bandung, Indonesia
🇮🇩Rumah Sakit TNI AU Soemitro, Surabaya, Indonesia
🇮🇩Rumah Sakit Islam Pd. Kopi, Jakarta, Indonesia
Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #2
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03413592
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Fukuoka, Japan
Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03278080
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Fukuoka, Japan
© Copyright 2024. All Rights Reserved by MedPath